Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
life sciences
3
×
national blog main
boston
boston blog main
boston top stories
clinical trials
dyne therapeutics
fda
myotonic dystrophy type 1
rare disease drugs
san diego blog main
san francisco blog main
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech ipos
bluebird bio
deals
duchenne muscular dystrophy
facioscapulohumeral muscular dystrophy
food and drug administration
gene therapy
joshua brumm
kaleido biosciences
medical device
metacrine
muscular dystrophy
national top stories
new york blog main
nonalcoholic steatohepatitis
pulmonary arterial hypertension
raleigh-durham blog main
rare diseases
romesh subramanian
salk institute
san diego top stories
san francisco
san francisco top stories
What
drug
rare
3
×
therapeutics
dyne
genetic
ipo
medicines
muscle
ago
biotechs
brings
building
company
considering
data
deal
developer
developing
disease
diseases
disorders
dyne’s
early
established
expected
experimental
eyes
firm
having
humans
ipos
long
lung
million
momentum
muscular
pah
preclinical
raised
reach
Language
unset
Current search:
rare
×
biotech
×
" life sciences "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed